MedTrace Logo

Flutiform® Compared With Seretide® in the Treatment of COPD

NCT02195375 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 923

Last updated 2017-03-28

No results posted yet for this study

Summary

The purpose of this study is to investigate whether flutiform® is effective and safe in the treatment of chronic obstructive pulmonary disease (COPD).

Conditions

Interventions

DRUG

Flutiform 500/20 µg BID

DRUG

Flutiform 250/10 µg BID

DRUG

Seretide Accuhaler 50/500 µg BID

Sponsors & Collaborators

  • Mundipharma Research Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Australia
  • China
  • New Zealand
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195375 on ClinicalTrials.gov